miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis

Robert McCormick(John Radcliffe Hospital), Adrian L. Harris(John Radcliffe Hospital)
British Journal of Cancer
February 28, 2013
Cited by 188


Related Papers